Skip to content

Prospective Single-Arm Trial of Sentinel Lymph Node Biopsy and Radical Hysterectomy via vNOTES under Ureteral Fluorescence Guidance

Prospective Single-Arm Trial of Sentinel Lymph Node Biopsy and Radical Hysterectomy via vNOTES under Ureteral Fluorescence Guidance

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117078
Enrollment
Unknown
Registered
2026-01-19
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Experimental group:Undergo Radical Hysterectomy and Sentinel Lymph Node Resection via vNOTES under Ureteral Fluorescence Guidance

Sponsors

Chengdu Women's and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged 40–80 years. 2.Patients who have been pathologically and histologically diagnosed with cervical cancer at Stage ?A–?A, meet the indications for radical hysterectomy, and are scheduled to undergo sentinel lymph node biopsy and radical hysterectomy via vNOTES. 3.Patients classified as ASA Physical Status Class ?–? according to the American Society of Anesthesiologists (ASA) Physical Status Classification System. 4.Patients who are able to cooperate with the follow-up visits and related examinations specified in the protocol. 5.Patients and their family members have a full understanding of the purpose, procedures and risks of this study, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.A history of severe pelvic and abdominal adhesions that may interfere with surgical procedures. 2.Complicated with other malignant tumors. 3.Patients who are positive for human immunodeficiency virus (HIV) antibody; positive for hepatitis C virus (HCV) antibody; positive for Treponema pallidum antibody and judged by the investigators to have a relatively high risk of transmission. 4.Patients with severe systemic diseases who are deemed unfit for surgical treatment by the investigators. 5.Hypersensitivity to fluorescent tracers (e.g., indocyanine green). 6.Patients with mental illnesses who are unable to cooperate with the study. 7.Other circumstances that the investigators consider inappropriate for participation in this trial.

Design outcomes

Primary

MeasureTime frame
Fluorescent tracing effect;Surgical success rate;

Secondary

MeasureTime frame
Postoperative Recovery Indicators;Tumor Recurrence Status;Postoperative Quality of Life;

Countries

China

Contacts

Public ContactLin Yonghong

Chengdu Women's and Children's Central Hospital

1595669008@qq.com+86 28 8206 5470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026